Thermo Fisher raises 2026 outlook after 10% growth in Q2
Thermo’s Q2 performance was driven by its laboratory products and biopharma services business with profits around $6.69bn equating to a 12% uptick YoY.
24 July 2026
24 July 2026
Thermo’s Q2 performance was driven by its laboratory products and biopharma services business with profits around $6.69bn equating to a 12% uptick YoY.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.